Biomarkers of cognitive and memory decline in psychotropic drug users DOI Creative Commons
Monica Grigore, Mihai Andrei Ruscu, Dirk M. Hermann

et al.

Journal of Neural Transmission, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 8, 2024

Abstract Psychotropic drugs are vital in psychiatry, aiding the management of mental health disorders. Their use requires an understanding their pharmacological properties, therapeutic applications, and potential side effects. Ongoing research aims to improve efficacy safety. Biomarkers play a crucial role predicting memory decline psychotropic drug users. A comprehensive biomarkers, including neuroimaging, biochemical, genetic, cognitive assessments, is essential for developing targeted interventions preventive strategies. In this narrative review, we performed search on PubMed Google using review-specific terms. Clinicians should multifaceted approach, neurotransmitter analysis, neurotrophic factors, miRNA profiling, tasks early intervention personalized treatment. Anxiolytics' mechanisms involve various systems emerging targets. Research biomarkers anxiolytic users can lead detection intervention, enhancing clinical practices aligning with precision medicine. Mood stabilizer benefit from through RNA, neurophysiological, inflammatory promoting timely interventions. Performance-enhancing may boost athletic performance short term, but long-term risks ethical issues make problematic. Long-term enhancers athletes shows changes decline, necessitating ongoing monitoring Understanding these genetic influences helps pave way approaches prevent or mitigate deterioration, emphasizing importance screening based individual's profile. Future focus refining protective measures against deterioration. Overall,

Language: Английский

Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases DOI Open Access
Zheng Liu, Siyuan Song

Genes, Journal Year: 2025, Volume and Issue: 16(2), P. 135 - 135

Published: Jan. 24, 2025

Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s (PD), Huntington’s (HD), and amyotrophic lateral sclerosis (ALS), represent a growing societal challenge due to their irreversible progression significant impact on patients, caregivers, healthcare systems. Despite advances in clinical imaging-based diagnostics, these diseases are often detected at advanced stages, limiting the effectiveness of therapeutic interventions. Recent breakthroughs genomic transcriptomic technologies, including whole-genome sequencing, single-cell RNA sequencing (scRNA-seq), CRISPR-based screens, have revolutionized field, offering new avenues for early diagnosis personalized prognosis. Genomic approaches elucidated disease-specific genetic risk factors molecular pathways, while studies identified stage-specific biomarkers that correlate with severity. Furthermore, genome-wide association (GWAS), polygenic scores (PRS), spatial transcriptomics enabling stratification patients based profiles prognostic trajectories. Advances functional genomics uncovered actionable targets, ATXN2 ALS TREM2 AD, paving way tailored strategies. achievements, challenges remain translating discoveries into practice heterogeneity complexity neurodegenerative pathophysiology. Future integration technologies holds promise transforming diagnostic paradigms, hope improved patient outcomes precision medicine approaches.

Language: Английский

Citations

1
Micronuclei formation: small nuclear packages with big genomic consequences DOI
Andrew Omachoko Onoja, Christopher Didigwu Nwani, Chibuisi G. Alimba

et al.

The Nucleus, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Language: Английский

Citations

0
FTO inhibition mitigates high-fat diet-induced metabolic disturbances and cognitive decline in SAMP8 mice DOI Creative Commons
Alba Irisarri, Ana Corral,

Núria Perez-Salvador

et al.

Molecular Medicine, Journal Year: 2025, Volume and Issue: 31(1)

Published: Feb. 21, 2025

Abstract This study investigated the effects of fat mass and obesity-associated (FTO) inhibition on cognitive function metabolic parameters senescence-accelerated mouse prone 8 (SAMP8) mice fed a high-fat diet (HFD). SAMP8 an HFD exhibited increased body weight, impaired glucose tolerance, elevated serum leptin levels. In epididymal white adipose tissue (eWAT), pharmacological treatment with FB23, well-established FTO inhibitor, production modulated genes involved in lipid metabolism (Cpt1a, Atgl , Hsl Fas) oxidative stress (OS) ( Bip Edem ), inflammation (Mcp1, Tnfα) . Expression hepatic related to Mgl, Dgat2, Srebp Plin2) OS (catalase, Edem) were by although steatosis remained unchanged. Remarkably, FB23 m6A RNA methylation brain, accompanied changes N6-methyladenosine (m6A)-regulatory enzymes modulation neuroinflammatory markers (Il6, Mcp1, iNOS) reduced activity matrix metalloproteases (Mmp2, Mmp9) altered IGF1 signaling (Igf1, Pten) Notably, enhanced was observed through expression immediate early (Arc, Fos) transcription factor Stat3 Improved synaptic plasticity evident, as shown levels neurotrophic factors (Bdnf Ngf) restored neurite length spine density. Consistent these findings, behavioral tests demonstrated that effectively rescued impairments mice. The novel object recognition test (NORT) location (OLT) revealed treated short- long-term memory spatial compared control group. Additionally, open field showed reduction anxiety-like behavior after FB23. conclusion, ameliorated HFD-induced disturbances decline These results suggest targeting may be promising therapeutic approach counteract obesity-induced impairment age-related neurodegeneration.

Language: Английский

Citations

0
Brain 5-hydroxymethylcytosine alterations are associated with Alzheimer’s disease neuropathology DOI Creative Commons
Jinying Zhao, Tongjun Gu, Cheng Gao

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 22, 2025

5-hydroxymethylcytosine, also known as the sixth DNA base of genome, plays an important role in brain aging and neurological disorders such Alzheimer's disease. However, little is about its genome-wide distribution association with disease pathology. Here, we report a profiling 5-hydroxymethylcytosine 1079 autopsied brains (dorsolateral prefrontal cortex) older individuals assess multiple measures pathologies, including pathological diagnosis disease, amyloid-β load, PHFtau tangle density. Of 197,765 regions detected, identified 2821 differentially hydroxymethylated associated neuropathology after controlling for testing covariates. Many are located within loci, RIN3, PLCG2, ITGA2B, USP6NL. Integrative multi-omics analyses support potential mechanistic alterations Our study presents large-scale atlas offers insight into mechanism underlying pathogenesis. base, key authors over 1000 deceased to identify genes linked

Language: Английский

Citations

0
Epigenetic Biomarkers in Alzheimer's Disease: Diagnostic and Prognostic Relevance DOI
Tapan Behl,

Ashishkumar Kyada,

R Roopashree

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 102, P. 102556 - 102556

Published: Oct. 30, 2024

Language: Английский

Citations

3
Biomarkers of cognitive and memory decline in psychotropic drug users DOI Creative Commons
Monica Grigore, Mihai Andrei Ruscu, Dirk M. Hermann

et al.

Journal of Neural Transmission, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 8, 2024

Abstract Psychotropic drugs are vital in psychiatry, aiding the management of mental health disorders. Their use requires an understanding their pharmacological properties, therapeutic applications, and potential side effects. Ongoing research aims to improve efficacy safety. Biomarkers play a crucial role predicting memory decline psychotropic drug users. A comprehensive biomarkers, including neuroimaging, biochemical, genetic, cognitive assessments, is essential for developing targeted interventions preventive strategies. In this narrative review, we performed search on PubMed Google using review-specific terms. Clinicians should multifaceted approach, neurotransmitter analysis, neurotrophic factors, miRNA profiling, tasks early intervention personalized treatment. Anxiolytics' mechanisms involve various systems emerging targets. Research biomarkers anxiolytic users can lead detection intervention, enhancing clinical practices aligning with precision medicine. Mood stabilizer benefit from through RNA, neurophysiological, inflammatory promoting timely interventions. Performance-enhancing may boost athletic performance short term, but long-term risks ethical issues make problematic. Long-term enhancers athletes shows changes decline, necessitating ongoing monitoring Understanding these genetic influences helps pave way approaches prevent or mitigate deterioration, emphasizing importance screening based individual's profile. Future focus refining protective measures against deterioration. Overall,

Language: Английский

Citations

1